Are Inhaled Corticosteroids and Inhaled Corticosteroids/Long-acting β-Agonist of Use in Acute Asthma: an Update on Evidence

  • Neil G. Parikh
  • Sheena K. Maharaj
  • Travis Russell
  • Bradley E. ChippsEmail author
Allergic Asthma (DES Larenas-Linnemann de Martinez, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Allergic Asthma


Purpose of review

Treatment of acute asthma exacerbations involves using systemic corticosteroids and short-acting β2-agonists (SABA). In an effort to limit the burden of systemic steroids, recent studies suggest benefit with the use of inhaled corticosteroids in an acute asthma exacerbation.

Recent findings

Recent data has demonstrated benefit from the addition of inhaled corticosteroids to systemic steroids, increasing inhaled corticosteroid dose, and adding a separate inhaled corticosteroid inhaler during an exacerbation. Additionally, inhaled corticosteroid and fast-acting long-acting β-agonist (LABA) can be helpful when used in place of a SABA as a reliever of acute symptoms.


This review summarizes recent data that demonstrates potential uses of inhaled corticosteroids and inhaled corticosteroids/LABA for the treatment of acute asthma. Further studies are necessary to evaluate the role of inhaled corticosteroids alone and in combination with SABA and LABA across all asthma severities.


Asthma exacerbation Inhaled corticosteroids Inhaled corticosteroids/long-acting beta agonist 


Compliance with ethical standards

Conflict of interest

Bradley Chipps serves as a consultant and a member of speakers’ bureaus for AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron, Sanofi, and TEVA. Neil Parikh serves as a member of speaker’s bureau for Optinose and as a consultant for Astrazeneca, Aimmune, CSL Behring, Theravance. Sheena Maharaj and Travis Russell declare that they have no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Dougherty RH, Vahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy. 2009;39(2):193–202. Scholar
  2. 2.
    Global Initiative for Asthma. Global strategy for asthma management and prevention; 2019. Available from: Accessed 9 July 2019.
  3. 3.
    Salpeter SR, Ormiston T, Salpeter EE. Meta-analysis: respiratory tolerance to regular β2-agonist use in patients with asthma. Ann Intern Med. 2004;140:802–13.CrossRefGoogle Scholar
  4. 4.
    Van Grunsven PM, van Schayck CP, Molema J, et al. Effect of inhaled corticosteroids on bronchial responsiveness in patients with “corticosteroid naive” mild asthma: a meta-analysis. Thorax. 1999;54:316–22.CrossRefGoogle Scholar
  5. 5.
    U.S. Department of Health and Human Services, National Institutes of Health [Internet]. Expert Panel Report 3: guidelines for the diagnosis and management of asthma (EPR-3); 2007. Available from: Accessed 31 Jan 2019.
  6. 6.
    Beckhaus AA, Riutort M, Catro-Rodriguez JA. Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review. Pediatr Pulm. 2014;49:326–34. Scholar
  7. 7.
    Alangari A. Budesonide nebulization added to systemic prednisolone in the treatment of acute asthma in children. Chest. 2014;145(4):772–8.CrossRefGoogle Scholar
  8. 8.
    • Razi CH, Corut N, Andrian N. Budesonide reduces hospital admissions rates in preschool children with acute wheezing. Pediatr Pulmonol. 2017;52:720–8. The study shows budesonide may be beneficial in moderate to severe acute wheezing episodes.CrossRefGoogle Scholar
  9. 9.
    Milani GKM, Filho NAR, Riedi CA, Figueiredo BC. Nebulized budesonide to treat acute asthma in children. J Pediatr (Rio J). 2004;80(2):106–12.CrossRefGoogle Scholar
  10. 10.
    Edmonds ML, Millan SJ, Camargo CA Jr, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12.Google Scholar
  11. 11.
    Edmonds ML, Millan SJ, Brenner BE, Camargo CA Jr, Rowe BH. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev. 2012;12:CD002316.Google Scholar
  12. 12.
    Chew KS, Kamarudin H, Hashin CW. A randomized open-label trial on the use of budesonide/formoterol (SymbicortⓇ) as an alternative reliever medication for mild to moderate asthmatic attacks. Int J Emerg Med. 2012;5:16.CrossRefGoogle Scholar
  13. 13.
    Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther. 2006;19(2):139–47.CrossRefGoogle Scholar
  14. 14.
    • Kew KM, Quinn M, Quon BS, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2016;6:CD007524. Reviews the data on increasing inhaled corticosteroids during exacerbations.Google Scholar
  15. 15.
    Jackson DJ, Bacharier LB, Mauger DT, Boehmer S, Beigelman A, Chmiel JF, et al. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. N Engl J Med. 2018;378:891–901.CrossRefGoogle Scholar
  16. 16.
    McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med. 2018;378:902–10.CrossRefGoogle Scholar
  17. 17.
    O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non-bronchodilator effects of inhaled β2-agonists in asthma. N Engl J Med. 1992;327:1204–8. Scholar
  18. 18.
    Kraan J, Koeter GH. vd Mark TW, et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985;76:628–36.CrossRefGoogle Scholar
  19. 19.
    Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356:2040–52.CrossRefGoogle Scholar
  20. 20.
    O’Byrne PM, Fitzgerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. Scholar
  21. 21.
    Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–87.CrossRefGoogle Scholar
  22. 22.
    Papi A, Marku B, Schichilone N, et al. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomized, double-blind clinical trial. Lancet Respir Med. 2015;3:109–19.CrossRefGoogle Scholar
  23. 23.
    O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129–36.CrossRefGoogle Scholar
  24. 24.
    • Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting B-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319:1485–96. This paper is a meta-analysis of SMART versus inhaled corticosteroids with and without LABA as controller therapy for persistent asthma.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Neil G. Parikh
    • 1
  • Sheena K. Maharaj
    • 1
  • Travis Russell
    • 1
  • Bradley E. Chipps
    • 1
    Email author
  1. 1.Capital Allergy and Respiratory Disease CenterSacramentoUSA

Personalised recommendations